{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:29:52Z","timestamp":1787657392422,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Due to their broad-spectrum activities, ivermectin and moxidectin are widely used anthelminthics in veterinary and human medicine. However, ivermectin has recently been shown to perturbate bacterial growth. Given the macrolide-like structure of both ivermectin and moxidectin, there is a need to characterize the antibiotic spectrum of these anthelminthics and their potential implications in the development of cross-resistance to macrolides and other families of antibiotics. Here, we characterize growth dynamics of 59 bacterial isolates in presence of ivermectin and moxidectin. Further, we assessed the effect of repeated anthelminthic exposure in 5 bacterial isolates on sensitivity to different antibiotics, both via growth dynamics and minimal inhibitory concentration. We found, that anthelminthic growth phenotypes are comparable to a selection of tested antibiotics. Bacterial anthelminthic challenging resulted in decreased anthelminthic sensitivity, and to some extent, decreased antibiotic sensitivity. Hence, potential off-target effects of large-scale administration of ivermectin and moxidectin should be carefully monitored.<\/jats:p>","DOI":"10.1038\/s42003-024-07135-z","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T04:47:14Z","timestamp":1732682834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exposure of gut bacterial isolates to the anthelminthic drugs, ivermectin and moxidectin, leads to antibiotic-like phenotypes of growth inhibition and adaptation"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2448-3795","authenticated-orcid":false,"given":"Julian","family":"Dommann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-3521","authenticated-orcid":false,"given":"Jennifer","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4579-8776","authenticated-orcid":false,"given":"Julian","family":"Garneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Gandelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somphou","family":"Sayasone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-6505","authenticated-orcid":false,"given":"Pascale","family":"Vonaesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8586-4937","authenticated-orcid":false,"given":"Pierre H. H.","family":"Schneeberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"7135_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0140-6736(17)31930-X","volume":"391","author":"PM Jourdan","year":"2018","unstructured":"Jourdan, P. M. et al. Soil-transmitted helminth infections. Lancet 391, 252\u2013265 (2018).","journal-title":"Lancet"},{"key":"7135_CR2","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(18)32981-7","volume":"393","author":"J Keiser","year":"2019","unstructured":"Keiser, J. & Utzinger, J. Community-wide soil-transmitted helminth treatment is equity-effective. Lancet 393, 2011\u20132012 (2019).","journal-title":"Lancet"},{"key":"7135_CR3","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/0035-9203(95)90101-9","volume":"89","author":"M Albonico","year":"1995","unstructured":"Albonico, M. et al. Rate of reinfection with intestinal nematodes after treatment of children with mebendazole or albendazole in a highly endemic area. Trans. R. Soc. Trop. Med. Hyg. 89, 538\u2013541 (1995).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"7135_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1179\/136485909X398212","volume":"103","author":"CC Appleton","year":"2009","unstructured":"Appleton, C. C. et al. Geohelminth infection and re-infection after chemotherapy among slum-dwelling children in Durban, South Africa. Ann. Trop. Med. Parasitol. 103, 249\u2013261 (2009).","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"7135_CR5","doi-asserted-by":"publisher","first-page":"e1621","DOI":"10.1371\/journal.pntd.0001621","volume":"6","author":"TW Jia","year":"2012","unstructured":"Jia, T. W. et al. Soil-transmitted helminth reinfection after drug treatment: a systematic review and meta-analysis. PLoS Negl. Trop. Dis. 6, e1621 (2012).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"7135_CR6","doi-asserted-by":"publisher","first-page":"e0003895","DOI":"10.1371\/journal.pntd.0003895","volume":"10","author":"PJ Hotez","year":"2016","unstructured":"Hotez, P. J. et al. Eliminating the neglected tropical diseases: translational science and new technologies. PLoS Negl. Trop. Dis. 10, e0003895 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"7135_CR7","doi-asserted-by":"publisher","first-page":"j4307","DOI":"10.1136\/bmj.j4307","volume":"358","author":"W Moser","year":"2017","unstructured":"Moser, W., Schindler, C. & Keiser, J. Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis. BMJ 358, j4307 (2017).","journal-title":"BMJ"},{"key":"7135_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/bs.apar.2018.08.002","volume":"103","author":"W Moser","year":"2019","unstructured":"Moser, W., Schindler, C. & Keiser, J. Drug combinations against soil-transmitted helminth infections. Adv. Parasitol. 103, 91\u2013115 (2019).","journal-title":"Adv. Parasitol."},{"key":"7135_CR9","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1001\/jama.299.16.1937","volume":"299","author":"J Keiser","year":"2008","unstructured":"Keiser, J. & Utzinger, J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 299, 1937\u20131948 (2008).","journal-title":"JAMA"},{"key":"7135_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eclinm.2018.06.004","volume":"1","author":"MS Palmeirim","year":"2018","unstructured":"Palmeirim, M. S. et al. Efficacy and safety of a single dose versus a multiple dose regimen of mebendazole against hookworm infections in children: a randomised, double-blind trial. eClinicalMedicine 1, 7\u201313 (2018).","journal-title":"eClinicalMedicine"},{"key":"7135_CR11","doi-asserted-by":"publisher","first-page":"e1138","DOI":"10.1371\/journal.pntd.0001138","volume":"5","author":"P Olliaro","year":"2011","unstructured":"Olliaro, P. et al. Potential drug development candidates for human soil-transmitted helminthiases. PLoS Negl. Trop. Dis. 5, e1138 (2011).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"7135_CR12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.tibs.2018.06.011","volume":"43","author":"N V\u00e1zquez-Laslop","year":"2018","unstructured":"V\u00e1zquez-Laslop, N. & Mankin, A. S. How macrolide antibiotics work. Trends Biochem. Sci. 43, 668\u2013684 (2018).","journal-title":"Trends Biochem. Sci."},{"key":"7135_CR13","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/14787210.2020.1792772","volume":"18","author":"P Milton","year":"2020","unstructured":"Milton, P. et al. Moxidectin: an oral treatment for human onchocerciasis. Expert Rev. Anti Infect. Ther. 18, 1067\u20131081 (2020).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"7135_CR14","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S1473-3099(20)30691-5","volume":"21","author":"D Hofmann","year":"2021","unstructured":"Hofmann, D. et al. Efficacy and safety of ascending doses of moxidectin against Strongyloides stercoralis infections in adults: a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial. Lancet Infect. Dis. 21, 1151\u20131160 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"7135_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1473-3099(23)00507-8","volume":"24","author":"VP Sprecher","year":"2023","unstructured":"Sprecher, V. P. et al. Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b\/3 trial. Lancet Infect. Dis. 24, 196\u2013205 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"7135_CR16","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/cid\/ciz326","volume":"70","author":"L Keller","year":"2020","unstructured":"Keller, L. et al. Efficacy and safety of ascending dosages of moxidectin and moxidectin-albendazole against Trichuris trichiura in adolescents: a randomized controlled trial. Clin. Infect. Dis. 70, 1193\u20131201 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"7135_CR17","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1086\/657310","volume":"51","author":"S Knopp","year":"2010","unstructured":"Knopp, S. et al. Albendazole and Mebendazole administered alone or in combination with Ivermectin against Trichuris trichiura: a randomized controlled trial. Clin. Infect. Dis. 51, 1420\u20131428 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"7135_CR18","unstructured":"World Health Organization (WHO), Assessing the efficacy of anthelminthic drugs against schistosomiasis and soil-transmitted helminthiases. https:\/\/www.who.int\/publications\/i\/item\/9789241564557 (2013)."},{"key":"7135_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrmicro.2016.17","volume":"14","author":"P Spanogiannopoulos","year":"2016","unstructured":"Spanogiannopoulos, P. et al. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat. Rev. Microbiol. 14, 273\u2013287 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"7135_CR20","doi-asserted-by":"publisher","DOI":"10.15252\/msb.202010116","volume":"17","author":"M Zimmermann","year":"2021","unstructured":"Zimmermann, M. et al. Towards a mechanistic understanding of reciprocal drug\u2013microbiome interactions. Mol. Syst. Biol. 17, e10116 (2021).","journal-title":"Mol. Syst. Biol."},{"key":"7135_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nature25979","volume":"555","author":"L Maier","year":"2018","unstructured":"Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623\u2013628 (2018).","journal-title":"Nature"},{"key":"7135_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28658-1","volume":"13","author":"PHH Schneeberger","year":"2022","unstructured":"Schneeberger, P. H. H. et al. Different gut microbial communities correlate with efficacy of albendazole-ivermectin against soil-transmitted helminthiases. Nat. Commun. 13, 1063 (2022).","journal-title":"Nat. Commun."},{"key":"7135_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13756-018-0314-4","volume":"7","author":"S Ashraf","year":"2018","unstructured":"Ashraf, S. et al. In vitro activity of ivermectin against Staphylococcus aureus clinical isolates. Antimicrob. Resist Infect. Control 7, 27 (2018).","journal-title":"Antimicrob. Resist Infect. Control"},{"key":"7135_CR24","doi-asserted-by":"publisher","first-page":"e20904","DOI":"10.2196\/20904","volume":"9","author":"ED Dabira","year":"2020","unstructured":"Dabira, E. D. et al. Mass drug administration with high-dose Ivermectin and Dihydroartemisinin-Piperaquine for malaria elimination in an area of low transmission with high coverage of malaria control interventions: protocol for the MASSIV cluster randomized clinical trial. JMIR Res. Protoc. 9, e20904 (2020).","journal-title":"JMIR Res. Protoc."},{"key":"7135_CR25","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.6617","volume":"5","author":"MR Smit","year":"2016","unstructured":"Smit, M. R. et al. Efficacy and safety of high-dose ivermectin for reducing malaria transmission (IVERMAL): protocol for a double-blind, randomized, placebo-controlled, dose-finding trial in Western Kenya. JMIR Res. Protoc. 5, e213 (2016).","journal-title":"JMIR Res. Protoc."},{"key":"7135_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s13071-022-05557-4","volume":"15","author":"HM Soumare","year":"2022","unstructured":"Soumare, H. M. et al. Entomological impact of mass administration of ivermectin and dihydroartemisinin-piperaquine in The Gambia: a cluster-randomized controlled trial. Parasit. Vectors 15, 435 (2022).","journal-title":"Parasit. Vectors"},{"key":"7135_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41587-023-01759-y","volume":"42","author":"YE Gencay","year":"2023","unstructured":"Gencay, Y. E. et al. Engineered phage with antibacterial CRISPR\u2013Cas selectively reduce E. coli burden in mice. Nat. Biotechnol. 42, 265\u2013274 (2023).","journal-title":"Nat. Biotechnol."},{"key":"7135_CR28","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1128\/AAC.01696-12","volume":"57","author":"LE Lim","year":"2013","unstructured":"Lim, L. E. et al. Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains. Antimicrob. Agents Chemother. 57, 1040\u20131046 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"7135_CR29","doi-asserted-by":"publisher","first-page":"e0003549","DOI":"10.1371\/journal.pntd.0003549","volume":"9","author":"TF Omansen","year":"2015","unstructured":"Omansen, T. F. et al. In-vitro activity of avermectins against Mycobacterium ulcerans. PLoS Negl. Trop. Dis. 9, e0003549 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"7135_CR30","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/antibiotics10020208","volume":"10","author":"X Tan","year":"2021","unstructured":"Tan, X. et al. A novel Ivermectin-derived compound D4 and its antimicrobial\/biofilm properties against MRSA. Antibiotics 10, 208 (2021).","journal-title":"Antibiotics"},{"key":"7135_CR31","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1177\/009127002237994","volume":"42","author":"CA Guzzo","year":"2002","unstructured":"Guzzo, C. A. et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J. Clin. Pharm. 42, 1122\u20131133 (2002).","journal-title":"J. Clin. Pharm."},{"key":"7135_CR32","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMc1901535","volume":"380","author":"T Doan","year":"2019","unstructured":"Doan, T. et al. Macrolide resistance in MORDOR I - a cluster-randomized trial in Niger. N. Engl. J. Med. 380, 2271\u20132273 (2019).","journal-title":"N. Engl. J. Med"},{"key":"7135_CR33","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41591-019-0533-0","volume":"25","author":"T Doan","year":"2019","unstructured":"Doan, T. et al. Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution. Nat. Med. 25, 1370\u20131376 (2019).","journal-title":"Nat. Med."},{"key":"7135_CR34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2022","unstructured":"Murray, C. J. L. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629\u2013655 (2022).","journal-title":"Lancet"},{"key":"7135_CR35","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMc1901535","volume":"380","author":"T Doan","year":"2019","unstructured":"Doan, T. et al. Macrolide resistance in MORDOR I \u2014 a cluster-randomized trial in Niger. N. Engl. J. Med. 380, 2271\u20132273 (2019).","journal-title":"N. Engl. J. Med."},{"key":"7135_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1756-3305-7-37","volume":"7","author":"RL Pullan","year":"2014","unstructured":"Pullan, R. L. et al. Global numbers of infection and disease burden of soil transmitted helminth infections in 2010. Parasit. Vectors 7, 37 (2014).","journal-title":"Parasit. Vectors"},{"key":"7135_CR37","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S2542-5196(21)00280-1","volume":"5","author":"AJ Browne","year":"2021","unstructured":"Browne, A. J. et al. Global antibiotic consumption and usage in humans, 2000-18: a spatial modelling study. Lancet Planet Health 5, 893\u2013904 (2021).","journal-title":"Lancet Planet Health"},{"key":"7135_CR38","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1086\/324626","volume":"34","author":"R Leclercq","year":"2002","unstructured":"Leclercq, R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin. Infect. Dis. 34, 482\u2013492 (2002).","journal-title":"Clin. Infect. Dis."},{"key":"7135_CR39","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10620-020-06118-4","volume":"65","author":"W Ruan","year":"2020","unstructured":"Ruan, W. et al. Healthy human gastrointestinal microbiome: composition and function after a decade of exploration. Dig. Dis. Sci. 65, 695\u2013705 (2020).","journal-title":"Dig. Dis. Sci."},{"key":"7135_CR40","doi-asserted-by":"publisher","first-page":"a025395","DOI":"10.1101\/cshperspect.a025395","volume":"6","author":"C Fyfe","year":"2016","unstructured":"Fyfe, C. et al. Resistance to macrolide antibiotics in public health pathogens. Cold Spring Harb. Perspect. Med. 6, a025395 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"7135_CR41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1574-6968.2008.01145.x","volume":"282","author":"MC Roberts","year":"2008","unstructured":"Roberts, M. C. Update on macrolide\u2013lincosamide\u2013streptogramin, ketolide, and oxazolidinone resistance genes. FEMS Microbiol. Lett. 282, 147\u2013159 (2008).","journal-title":"FEMS Microbiol. Lett."},{"key":"7135_CR42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0732-8893(96)00183-6","volume":"26","author":"VD Shortridge","year":"1996","unstructured":"Shortridge, V. D. et al. Novel mechanism of macrolide resistance in Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 26, 73\u201378 (1996).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"7135_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1104707","volume":"14","author":"PT Asare","year":"2023","unstructured":"Asare, P. T. et al. A MALDI-TOF MS library for rapid identification of human commensal gut bacteria from the class Clostridia. Front. Microbiol. 14, 1104707 (2023).","journal-title":"Front. Microbiol."},{"key":"7135_CR44","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41592-022-01520-4","volume":"19","author":"KD Curry","year":"2022","unstructured":"Curry, K. D. et al. Emu: species-level microbial community profiling of full-length 16S rRNA Oxford Nanopore sequencing data. Nat. Methods 19, 845\u2013853 (2022).","journal-title":"Nat. Methods"},{"key":"7135_CR45","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s10646-019-02107-0","volume":"28","author":"JJ Modrzy\u0144ski","year":"2019","unstructured":"Modrzy\u0144ski, J. J., Christensen, J. H. & Brandt, K. K. Evaluation of dimethyl sulfoxide (DMSO) as a co-solvent for toxicity testing of hydrophobic organic compounds. Ecotoxicology 28, 1136\u20131141 (2019).","journal-title":"Ecotoxicology"},{"key":"7135_CR46","doi-asserted-by":"publisher","unstructured":"Dommann, J. et al. Supplementary datasets (numerical source data) concerning the manuscript entitled \u201cExposure of gut bacterial isolates to the anthelminthic drugs, ivermectin and moxidectin, leads to antibiotic-like phenotypes of growth inhibition and adaptation.\u201d https:\/\/doi.org\/10.6084\/m9.figshare.27248703.v1 (2024).","DOI":"10.6084\/m9.figshare.27248703.v1"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-07135-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-07135-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-07135-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T05:14:14Z","timestamp":1732684454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-07135-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7135"],"URL":"https:\/\/doi.org\/10.1038\/s42003-024-07135-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.01.17.575993","asserted-by":"object"}]},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"22 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1566"}}